Bioinformatics Scientist, Dr. Paolo Ribeca, Joins Eyam Vaccines and Immunotherapeutics’ Scientific Advisory Board
January 27, 2021
Vancouver, British Columbia, Canada. January 27, 2021: Eyam Vaccines and Immunotherapeutics (EYAM) today announced that Dr. Paolo Ribeca, an expert in genomics, algorithms and bioinformatics, will be joining EYAM’s Scientific Advisory Board.
Ryan Thomas, CEO of Eyam, said, “Dr. Ribeca is co-inventor of a computational pipeline to design peptide-based vaccines. His integration into EYAM’s Scientific Advisory Board aligns with EYAM’s strategic plan to become a leader in the design and creation of next-generation RNA vaccines.”
Dr. Paolo Ribeca is a physicist by education, but for more than a decade has specialised in the analysis of high-throughput sequencing data, being particularly interested in the development of algorithms and pipelines for alignment and de-novo assembly. Currently, Dr. Ribeca’s research focuses on statistical genomics and bioinformatics at The James Hutton Institute.
“Dr. Ribeca has specialized in the production and analysis of next-generation sequencing data. His expertise in this area will have significant long-term implications for Eyam’s vaccine pipeline and will allow our research and development on vaccines to confront diseases with even greater precision,” Thomas said.
Dr. Ribeca has been a member of several international consortia that focused on studying genome structure and exploring the inner workings of the cell. While at the Pirbright Institute, he oversaw bioinformatics and sequencing; he researched the comparative genomics of a number of viral families, mechanisms of viral evolution, pathogenicity and attenuation, and the interaction between viruses, vectors and hosts.
Dr. Ribeca is also a member of the British Standards Institution and participates as an invited expert in the work of MPEG and MPAI (https://mpai.community) standardisation consortia, is Editor of part 6 of the MPEG-G (ISO/IEC 23092) standard on Representation and Compression of Genomic Information, and is also one of the founders of MPAI, and the proponent of the upcoming MPAI-GSA (Integrative Genomic/Sensor Analysis) standard.
He has more than 40 peer-reviewed publications, with more than 23,000 citations.
About Eyam Vaccines and Immunotherapeutics: Eyam Vaccines and Immunotherapeutics is a private, Canadian based company focused on the research and development of vaccines that are safe, efficacious and low dose. Eyam, was named to honour the village in Derbyshire that, in 1665-1666, chose to stay and brave near certain death rather than travelling and risk transmitting the plague to their neighbouring towns. In the end, 75% of Eyam’s residents did indeed die, but their surrounding neighbours were saved due to Eyam’s heroic and selfless quarantine. For further information see: https://royalsocietypublishing.org/doi/10.1098/rspb.2016.0618.
For further information:
Website: eyamhealth.com
Email: [email protected]
